Trials / Unknown
UnknownNCT05856409
Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- —
Summary
This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.
Detailed description
Gallium 68-labeled fibroblast-activation protein inhibitor (68Ga-FAPI) has recently been a potential radiotracer for gynecological malignancies,including ovarian cancer. Early detection and localization of sites of recurrence helps to identify ovarian cancer patients who will benefit the most from secondary surgery, chemotherapy, or radiation therapy. Its clinical utility for recurrence detection of epithelial ovarian cancer and histological validation of FAPI findings is not well established.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 68Ga-FAPI | \[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) |
Timeline
- Start date
- 2023-05-10
- Primary completion
- 2024-04-01
- Completion
- 2025-12-31
- First posted
- 2023-05-12
- Last updated
- 2023-08-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05856409. Inclusion in this directory is not an endorsement.